GlassScriptPhysician profile
Kyle O Rapp
NPI 1336101682
$6,654.76
in general payments reported to CMS, 2019-2025
50 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $941 · 2021: $1,199 · 2022: $676 · 2023: $1,029 · 2024: $879 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,852 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,852.34 |
| Education | $124.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.53 | 2021-2025 | |
| Novo Nordisk INC | $596.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $482.91 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Amgen INC. | $366.44 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.39 | 2020-2024 | Synjardy, Jardiance |
| Otsuka America Pharmaceutical, INC. | $333.05 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $303.05 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $284.12 | 2019-2025 | |
| Lilly USA, LLC | $231.93 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $228.91 | 2022-2025 | Caplyta |
| Allergan, INC. | $195.42 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.61 | 2019-2023 | Trintellix |
| Lundbeck LLC | $184.45 | 2022-2025 | Rexulti, Vyepti |
| Horizon Therapeutics Plc | $182.62 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.33 | 2019-2025 | Xifaxan, Trulance |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Rapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.